Market News AIOpen the app

Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome

TrialRead the original at prnewswire.com
Good for ELOX

Eloxx's study found more collagen IV and partly improved kidney-cell shape in all 3 participants, with no serious side effects reported. The study was very small, but the early results support its ongoing trial.

ELOX · Eloxx Pharmaceuticals

AI read · Good for ELOX

The AI's read

The findings give Eloxx early evidence that exaluren reaches its intended target, and the reported safety results add support. Only 3 people took part, so the study cannot show whether patients will gain lasting kidney benefits. Still, it supports testing exaluren in the ongoing Phase 2b study.

Get alerts for ELOX

Follow Eloxx Pharmaceuticals (ELOX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ELOX
Free on the App Store and Google Play, or on the web.